Glaxo Gives Up One Of Three Patents For Avandia In China

Law360, New York (August 18, 2004, 12:00 AM EDT) -- U.K. drug maker GlaxoSmithKline has abandoned its claim to a Chinese patent for a component of its popular diabetes drug Avandia, but is holding on to two other patents on the drug in an escalating battle with Chinese generic makers.

Glaxo dropped a countersuit against Chinese drugmakers, which challenged its patent for rosiglitazone, one of three patented ingredients in Avandia, a spokeswoman for the company told local media and newswires.

She did not give a reason for the decision, but the lawyer for the Chinese companies...
To view the full article, register now.